Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008 Nov 25;71(22):1770-5. PubMed.
Recommends
Please login to recommend the paper.
Comments
It would be appropriate to try doing a trial of IGF-1 BP3
View all comments by Deborah Gattoni(Iplex) at a
higher dose. As ALS patients, many of us do not have two years
to waste on
stupidity. I used Iplex briefly before the lawsuit rendered it
unavailable. My "anecdotal" evidence supported slight improvement
in a short period of
time. Worth a shot when it comes to people waiting to die,
isn't it?
Make a Comment
To make a comment you must login or register.